NR2C and NR2D Subunit-Selective NMDA Potentiators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NMDA receptor potentiators lack subunit selectivity, leading to non-specific effects and potential side effects, while there is a need for targeted therapeutic agents that can enhance specific NMDA receptor functions in neurological disorders without affecting other brain regions.
Innovation Solution
Development of NMDA receptor potentiators specific to NR2C and NR2D subunits, which selectively enhance NMDA receptor activity in specific brain regions, reducing side effects by targeting only those subunits involved in neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective NMDA receptor potentiators are used, then NMDA receptor activity is enhanced, but side effects increase due to non-specific effects across all brain regions
Solution Approach 1:
The patent segments the NMDA receptor system by developing potentiators that selectively target specific NR2 subunits (NR2A, NR2B, NR2C, or NR2D). This segmentation allows the therapeutic agent to act on only the relevant subunit involved in the neurological disorder, leaving other subunits unaffected, thereby reducing non-specific side effects while maintaining therapeutic efficacy.
Solution Approach 2:
The patent applies local quality by creating potentiators with subunit-specific binding properties. Each potentiator is designed to bind preferentially to a particular NR2 subunit type, enabling localized modulation of NMDA receptor function in brain regions where that specific subunit is expressed, rather than uniformly affecting all NMDA receptors throughout the brain.
2Object-affected harmful factors
If subunit-selective potentiators are developed, then side effects are reduced, but device complexity increases due to need for specific subunit targeting
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of potentiator molecules to achieve subunit selectivity. By changing specific molecular parameters (functional groups, stereochemistry, binding affinity characteristics), the potentiators gain the ability to distinguish between different NR2 subunits while maintaining reasonable structural complexity for drug development.
Data Source
AI summary
Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.